SAS and Carolina partner to accelerate antiviral drug development

Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI). (UNC.edu)

Related: Campus Connections

For Tift Merritt, Time and Patience Have Made the Difference
Tift Merritt never thought she’d end up back in her hometown of Raleigh, North Carolina. For about 15 years she toured through America and Europe...
Sun Feb 15, 2026

Rich Eisen can’t bring himself to watch Stuart Scott ’30 for 30' yet
ESPN’s latest 30 for 30 documentary stays close to home, covering the life of Stuart Scott, an icon of the Worldwide Leader’s SportsCenter era. Rich...
Sun Feb 15, 2026

UNC business, nursing online programs rank among nation’s best
The 2026 U.S. News & World Report Best Online Program Rankings place online master’s programs from UNC Kenan-Flagler Business School and the UNC School of...
Sat Feb 14, 2026

Gift from UNC alums will fund 20 Carolina Covenant scholars
A transformational estate gift from Dwight Jacobs ’87 and Moira Jacobs ’87 will support future generations of Carolina Covenant scholars. “If we could help 20...
Mon Feb 9, 2026